EGFR and non-small cell lung carcinoma: One of the challenges of studying MET-directed therapies for osimertinib-resistant EGFR-mutant NSCLC is lack of relevant preclinical models, as the current evidence for MET-directed therapies is largely based on in vitro model systems (13).